To: All Persons or Entities who purchased Juniper Pharmaceuticals, Inc. (“Juniper” or the “Company”) (NASDAQGS: JNP) stock prior to July 3, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the Juniper merger. Juniper will be sold to Catalent Inc. (NYSE: CTLT) (“Catalent”). Under the terms of the transaction, Juniper shareholders will receive $11.50 for each share of Juniper common stock that they own. To learn more about the JNP merger and your rights, go to: http://www.zlk.com/mna/juniper-pharmaceuticals-inc or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Juniper Pharmaceuticals, Inc. breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Catalent is underpaying for Juniper shares, thus unlawfully harming Juniper shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.